MetaCap

BeyondSpring Inc. Company Profile

NASDAQ: BYSIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.33-0.107 (-24.49%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BeyondSpring at a glance

BeyondSpring Inc. (NASDAQ: BYSI) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Florham Park, NJ. BeyondSpring is led by Mr. Min Qiu and employs about 44 people. The company's shares have traded publicly since 2017.

At a market capitalization of $13.7 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001677940, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does BeyondSpring do?

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Business description based on the company's public filings.

Company information

Legal name
BeyondSpring Inc.
Ticker
NASDAQ: BYSI
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Min Qiu
Employees
44
Headquarters
100 Campus Drive, Florham Park, NJ, United States
Phone
646 305 6387
IPO year
2017
Market cap
$13.66M
SEC CIK
0001677940
Latest annual report
10-K · Mar 25, 2026

Companies similar to BeyondSpring

BYSI peer companies
CompanyPrice% ChgMarket capCompare
ACTUActuate Therapeutics Inc.0.2253+5.38%$13.60Mvs BYSI
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs BYSI
TVRDTvardi Therapeutics Inc.0.9893+4.57%$13.22Mvs BYSI
BOLTBolt Biotherapeutics Inc.4.91-2.96%$12.80Mvs BYSI
NEUPNeuphoria Therapeutics Inc.2.35+1.29%$12.72Mvs BYSI
NCELNewcelX Ltd.2.54-5.58%$14.67Mvs BYSI
MCRBSeres Therapeutics Inc.1.24-6.77%$12.64Mvs BYSI
CNTXContext Therapeutics Inc.0.16-5.10%$14.70Mvs BYSI

Related